Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
05 March 1992Website:
http://www.lineagecell.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 22 min agoDividend
Analysts recommendations
Institutional Ownership
LCTX Latest News
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - CFO Conference Call Participants Joe Pantginis - H.C Wainwright Jack Allen - Baird Kristen Kluska - Cantor Fitzgerald Mayank Mamtani - B. Riley Sean McCutcheon - Raymond James Michael Okunewitch - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Fourth Quarter and Fiscal Year-End 2023 Conference Call.
Start Time: 16:30 January 1, 0000 5:12 PM ET Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q3 2023 Earnings Conference Call November 09, 2023, 16:30 PM ET Company Participants Brian Culley - CEO Jill Howe - CFO Gary Hogge - SVP, Clinical and Medical Affairs Ioana Hone - Head, IR Conference Call Participants Joseph Pantginis - H.C. Wainwright Abigail Gray - Baird Kristen Kluska - Cantor Fitzgerald Operator Welcome to the Lineage Cell Therapeutics Third Quarter 2023 Conference Call.
Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing cell therapies for degenerative diseases. The shares trade for just over a buck apiece. Five analyst firms have reissued Buy/Outperform ratings on the stock, with price targets ranging from $4.00 to $7.00 a share. The company is partnered with Genentech around its main developmental program and that is targeting a large potential market.
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.04 per share a year ago.
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Gary Hogge - Senior Vice President of Clinical and Medical Affairs Conference Call Participants Jack Allen - Baird Joe Joe Pantginis - H. C. Wainwright Kristen Kluska - Cantor William Wood - B.
Penny stocks to buy have been the talk of the town in recent weeks as cyclical assets have started to make a comeback this year. Penny stocks tend to perform poorly during market downturns.
What type of business is Lineage Cell Therapeutics?
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
What sector is Lineage Cell Therapeutics in?
Lineage Cell Therapeutics is in the Healthcare sector
What industry is Lineage Cell Therapeutics in?
Lineage Cell Therapeutics is in the Biotechnology industry
What country is Lineage Cell Therapeutics from?
Lineage Cell Therapeutics is headquartered in United States
When did Lineage Cell Therapeutics go public?
Lineage Cell Therapeutics initial public offering (IPO) was on 05 March 1992
What is Lineage Cell Therapeutics website?
https://www.lineagecell.com
Is Lineage Cell Therapeutics in the S&P 500?
No, Lineage Cell Therapeutics is not included in the S&P 500 index
Is Lineage Cell Therapeutics in the NASDAQ 100?
No, Lineage Cell Therapeutics is not included in the NASDAQ 100 index
Is Lineage Cell Therapeutics in the Dow Jones?
No, Lineage Cell Therapeutics is not included in the Dow Jones index
When does Lineage Cell Therapeutics report earnings?
The next expected earnings date for Lineage Cell Therapeutics is 09 August 2024